Palantir Earnings Preview: Bullish Thesis vs. Fundamental Risks

What happened

A Seeking Alpha earnings preview reiterates a Buy rating on Palantir with a $224 price target, citing 109% US Commercial revenue growth in FY25 and guidance for 115% growth in FY26, and arguing that rapid earnings growth will support multiple compression even at a forward P/E of 108x. However, the DeepValue Master Report assigns a WAIT rating, highlighting that at $143, the stock prices in sustained hyper-growth but faces material risks from contract cancelability (RPO conversion at ~38% in 12 months, many contracts terminable for convenience) and competitive pressure from hyperscalers bundling at zero or negative margins. The report further notes that the next 6-12 months are critical, with Q1'26 results due May 4 and the DoD Maven transition deadline by Sep 2026. The preview overlooks these enforceability and competitive threats, focusing solely on top-line momentum and valuation compression. The fundamental disconnect between the bullish surface narrative and the underlying contractual fragility suggests the market is not fully pricing in downside scenarios.

Implication

Investors should remain cautious as Palantir's high valuation (P/E >200x) depends on flawless execution on both commercial and government fronts. The DeepValue report's WAIT rating underscores that the stock's upside is contingent on sustained US Commercial momentum and successful Maven transition, both of which are unproven at scale. While the earnings preview paints an optimistic picture, the risk of revenue deceleration from competitive bundling or contract cancellations is real. The prudent approach is to wait for observable evidence from Q1'26 earnings (May 4) and RPO conversion metrics before initiating or adding to positions. The attractive entry zone identified in the report is $120, offering a 16% downside from current levels, implying a better risk-reward after potential de-risking events.

Thesis delta

The prevailing market narrative, as reflected in the bullish preview, emphasizes revenue acceleration and valuation compression. However, our analysis indicates that the real test of the thesis lies in the quality of revenue visibility and competitive positioning—factors that are currently underappreciated. We shift from a growth-at-any-price view to a more skeptical stance, requiring evidence of durable commercial conversion and government program execution before endorsing the stock at current levels.